1. You Are At:
  2. English News
  3. India
  4. COVAXIN, India's indigenously developed Covid vaccine recommended for restricted emergency use

COVAXIN, India's indigenously developed Covid vaccine recommended for restricted emergency use

An expert panel on Saturday recommended granting permission for restricted emergency use authorisation for Bharat Biotech's indigenously developed COVID-19 vaccine — Covaxin.

India TV News Desk India TV News Desk
New Delhi Updated on: January 03, 2021 9:47 IST
COVAXIN, coronavirus vaccine
Image Source : FILE PHOTO

Expert panel recommends granting restricted emergency use approval for COVAXIN.

A day after a government panel recommended to grant emergency use approval for the Oxford-AstraZeneca's Covishield vaccine for coronavirus, an expert panel on Saturday recommended granting permission for restricted emergency use authorisation for Bharat Biotech's indigenously developed COVID-19 vaccine — Covaxin, ANI reported quoting government sources.

The Subject Expert Committee of Central Drug Standard Control Organization on Saturday recommended Bharat Biotech's 'Covaxin' for emergency use in India. The final decision on its approval will, however, be taken by the Drug Controller General of India (DCGI).

The committee of experts assessing Coronavirus vaccines had called Hyderabad-based Bharat Biotech for a meeting in the afternoon today, a day after the firm was asked to present more data to get a nod, a top source said on Saturday.

ALSO READCovid vaccination: Dry run across India, who will get it first, how to register | Everything you need to know

The Subject Expert Committee (SEC) of CDSCO has also recommended to DCGI for grant of permission for restricted emergency use of vaccine, subject to multiple regulatory conditionalities, to Serum Institute of India, Pune.

CDSCO recommends granting permission for restricted use in emergency situations in the public interest as an abundant precaution, in clinical trial mode, especially in the context of mutant strain infection, to Bharat Biotech & for the conduct of PhaseIII Clinical Trial Protocol to Cadila.

On Friday, the Subject Expert Committee of the Central Drug Standard Control Organisation (CDSCO) had held that the data provided by Bharat Biotech for its Coronavirus vaccine is not sufficient for grant of emergency use approval and asked for more information.

The expert committee, tasked with vetting Covid-19 vaccine proposals, had convened a meeting to take a call on emergency use authorisation sought by the Serum Institute of India and Bharat Biotech for their respective vaccine candidates.

Notably, the panel recommended emergency licensure for the Serum Institute of India-manufactured 'Covishield'. It become the first vaccine to secure recommendation for emergency use in India. The nod of the DCGI is, however, awaited on the recommendation.

The Pune-based Serum Institute has partnered with Oxford-AstraZeneca for conducting clinical trials and manufacturing 'Covishield' while Bharat Biotech has collaborated with the Indian Council of Medical Research (ICMR) for 'Covaxin'.

America's Pfizer was the first one to apply for the accelerated approval on December 4, followed by the Serum Institute and Bharat Biotech on December 6 and 7, respectively.

The Central government plans to vaccinate nearly 30 crore people in the first phase of drive. It will be offered to one crore healthcare workers, along with 2 crore frontline and essential workers and 27 crore elderly above the age of 50 years most of whom have co-morbidities.

ALSO READConfident of bringing vaccine around Makar Sankranti to defeat coronavirus: Yogi Adityanath

(With inputs from IANS)

Latest India News

Write a comment